Joaquim Bellmunt
Brigham and Women's Hospital(US)Beth Israel Deaconess Medical Center(US)Harvard University(US)Dana-Farber Cancer Institute(US)Hospital Del Mar(ES)Dana-Farber/Harvard Cancer Center(US)Dana-Farber Brigham Cancer Center(US)
Publications by Year
Research Areas
Bladder and Urothelial Cancer Treatments, Urinary and Genital Oncology Studies, Cancer Immunotherapy and Biomarkers, Renal cell carcinoma treatment, Prostate Cancer Treatment and Research
Most-Cited Works
- → Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial(2016)3,687 cited
- → Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma(2017)3,352 cited
- → EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent(2016)3,240 cited
- → Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer(2017)2,447 cited
- → MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer(2014)2,412 cited
- → Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial(2016)